top of page

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2022

Updated: Jul 20, 2023

REVENUES OF TOP BIOPHARMACEUTICAL COMPANIES - 2022

1 CHF = 1.01 USD, 1 GBP = 1.16USD; 1EUR= 0.99 USD; 1DKK = 0.13 USD; 1 JPY = 0.0075 USD

Merck revenues include only pharmaceuticals (excluding animal health)


Find latest healthcare and pharma news on Telegram now

Telegram channel QR code of ipharmacenter
iPharmaCenter Telegram


Top pharmaceutical companies by revenues in 2022 by different segments
Top pharmaceutical companies by revenues in 2022
 

PFIZER

Q1 REVENUES

Pfizer reported revenues of $25.7 billion in the first quarter of 2022, reflecting operational growth of 82%. The revenues from the vaccines segment were $14.94 billion, the hospital segment was $3.19 billion, the oncology segment was $2.97 billion, and immunology was $820 million.

The revenue drivers of the company were Comirnaty ($13.23 billion), Prevnar family ($1.57 billion), Paxlovid ($1.47 billion), Eliquis ($ 1.79 billion), and Ibrance ($1.24 billion).



H1 REVENUES

Pfizer reported revenues of $27.7 billion in the second quarter of 2022. Paxlovid and Comirnaty primarily drove the revenues.

The total revenues in the first half of 2022 were $53.4 billion. The vaccine segment contributed $25.4 billion, the hospital products segment (including Paxlovid) contributed $12.9 billion,

In the first half of 2022, Comirnaty revenues were $22.07 billion, Paxlovid was $9.6 billion, Ibrance was 2.5 billion, and Eliquis was $3.5 billion. Eliquis revenues increased by 13%, but Ibrance revenues dropped by 4%, and Xeljanz revenues reduced by 29%.



9 MONTHS

Pfizer announced the revenues of the third quarter, reporting revenues of $22.6 billion, revenues declined by 2% versus last year.

In the first nine months, the revenues were $76 billion. The revenues from Comirnaty were $26.5 billion, Paxlovid was $17 billion, Eliquis was $5 billion, Prevanar family was $4.6 billion, Ibrance was $3.8 billion, and Xeljanz was $1.3 billion.


12 MONTHS

Pfizer reported one-year revenues of $100.3 billion. The fourth-quarter revenues were $24.3 billion, an increase of 2%.



 

JOHNSON AND JOHNSON

Q1 RESULTS

Johnson and Johnson reported revenues of $23.4 billion in the first quarter of 2022, with sales growth of 5.0%. Pharmaceutical segment revenues were $12.87 billion, consumer health revenues were $3.59 billion, and Medtech revenues were $6.97 billion.

Stelara's revenues were $2.29 billion, and Darzalex's revenues were $1.86 billion.



H1 REVENUES

Johnson and Johnson reported revenues of $24 billion in the second quarter of 2022. The sales increased by 3%. Revenues from the pharmaceutical segment were $13.3 billion, MedTech was $6.9 billion, and consumer health was $3.8 billion. Darzalex, Stelara, and Tremfya primarily drove the sales.




Q3 REVENUES

Johnson and Johnson reported revenues of $23.8 billion, with a growth of 1.9%. The pharmaceutical segment grew by 2.6%, with reported revenues of $13.21. MedTech was increased by 2.1%($6.8 billion), and consumer health revenues were reduced by 0.4% ($3.8 billion).



12 MONTHS

Johnson and Johnson reported annual revenues of $94.3 billion in 2022. The revenues increased by 6.2%. The pharmaceutical segment revenues were $52.6 billion, revenues from consumer health were $15.0 billion, and MedTech sales were $27.4 billion.

 

ROCHE

Q1 RESULTS

Roche sales increased by 11% at a constant exchange rate; pharmaceutical sales increased by 6%, and the diagnostics division grew by 24%. In the US, the pharmaceutical division sales increased by 2%, decreased by 1% in Europe, and increased by 69% in Japan primarily because of the high demand of COVID19 drug Ronapreve.

The main revenue drivers in the pharmaceutical segment were Ocrevus ($1.5 billion), Perjeta ($1.03 billion), Hemlibra ($0.89 billion), Tecentriq ($0.86 billion), and Actemra ($0.83 billion).



However, the company's full-year outlook mentioned sales growth in the low single digits, primarily because of a decrease in the demand for COVID19 drugs and diagnostics (sales decrease from CHF 2 billion 5 billion), plus losses due to biosimilars (CHF 2.5 billion).


H1 REVENUES

Roche announced that the revenues were increased by 5% at CER in the first six months of 2022. The pharmaceutical division sales were increased by 3%, diagnostics sales increased by 11%. Ocrevus was the best selling drug with revenues of CHF 2.9 billion. Other best selling products were Perjeta (CHF 2 billion), Hemlibra (CHF 1.83 billion), and Tecentriq (CHF 1.8 billion).



9 MONTHS REVENUES

Roche reported nine months of revenues; the group sales increased by 2% at CER. The company reported revenues of $47.3 billion, the pharmaceutical segment contributed $33.3 billion (a contraction in sales by -1% in CHF), and diagnostics contributed $13.9 billion.

The company emphasized that the revenue reduction is because of a decrease in demand for COVID-19 diagnostics and medicines.

The company announced that the sales were driven by Ocrevus ($4.4 billion), Hemlibra ($2.8 billion), and Evrysdi ($0.8 billion). However, Avastin, Rituxan, and Herceptin biosimilars had a negative impact on revenues.


12 MONTHS REVENUES

Roche reported revenues of $68.6 billion in 2022, an increase of 2% at CER.

 

ABBVIE

Q1 RESULTS

AbbVie's Q1 revenues in 2022 were $13.5 billion, an increase of 4.1%. The revenues from the immunology portfolio were $6.14 billion, neuroscience was $1.5 billion, and hematologic oncology was $1.65 billion.

Humira revenues were $3.99 billion, Imbruvica was $1.17 billion, and Skyrizi was $0.94 billion.


H1 REVENUES

AbbVie reported an increase in revenues of 21.4% in the second quarter of 2022. The company reported revenues of $14.53 billion. Humira revenues were $10.09 billion, Skyrizi was $2.19 billion, and Imbruvica was $2.3 billion.


9 MONTHS

AbbVie reported third-quarter revenues of $14.8 billion, an increase of 3.3% versus last year. The major revenue drivers were Humira ($5.5 billion), Skyrizi ($1.4 billion), and Imbruvica ($1.1 billion).

For nine months, AbbVie reported revenues of $42.9 billion. Humira revenues from the first nine months were $15.7 billion, Skyrizi was $3.6 billion, and Imbruvica was $3.4 billion. Rinvoq recorded sales of$1.8 billion, and Venclexta's revenues were $1.5 billion.

Skyrizi's revenues increased by 76%, whereas Rinvoq's revenues increased by 55%.


 

MERCK

Q1 RESULTS

Merck reported revenues of $15.9 billion, and the pharmaceutical segment contributed $14.1 billion. Animal health contributed revenues of $1.5 billion.

The sales were primarily driven by Keytruda ($4.8 billion) and Lagevrio ($3.25 billion).


H1 REVENUES

Merck reported revenues of $26.86 billion in the first six months of 2022. Keytruda's revenues were $10.06 billion (an increase of 26%) in the first six months of 2022. Gardasil revenues were $3.1 billion, and Lagevrio was $4.4 billion.



9 MONTHS

In the third quarter, the pharmaceutical segment of Merck reported revenues of $13 billion, an increase of 13% versus 2021. Keytruda reported revenues of $5.4 billion, Gardasil of $2.3 billion,

The revenues from the pharmaceutical segment in the first nine months were $39.8 billion. The revenues from Keytruda were $15.5 billion, Gardasil/Gardasil 9 was $5.4 billion, and Januvia was $2.2 billion.

The revenues of Keytruda were grown by 20%, and there was a strong momentum from metastatic indications, including certain types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, TNBC, and MSI-H cancers.


 

NOVARTIS

Q1 RESULTS

Novartis sales increased by 5% at a constant exchange rate; innovative medicines sales grew by 4%.

The main revenue drivers are Cosentyx ($1.16 billion), Entresto ($1.09 billion), Gilenya ($0.6 billion), and Lucentis ($0.52 billion).


H1 REVENUES

Novartis reported an increase of 5% in sales in the second quarter of 2022. The company reported revenues of $12.78 billion, and the total revenues in the H1 of 2022 were $25.3 billion.

In the H1 of 2022, revenues from Cosentyx were $2.4 billion, Entresto was $2.2 billion, and Gilenya was $1.16 billion. Kesimpta's revenues were grown by 280% ($ 434 million), Entresto's by 37%, and Kisqali's by 36% ($ 547 million).



9 MONTHS

Novartis presented the revenues of the third quarter, with revenues declining by 4% in terms of USD. The company reported revenues of $12.5 billion versus $13.03 billion last year.

For the nine months, the company reported a revenue drop of 1%; reported revenues of $37.9 billion versus $38.4 billion last year. The growth drivers of Novartis were Cosentyx ($3.7 billion) and Entresto ($3.4 billion).


 

ABBOTT

Q1 RESULTS

Abbott reported revenues of $11.90 billion in Q1 of 2022. The sales from the nutrition segment were $1.89 billion, diagnostics were $5.29 billion, medical devices were $3.57 billion, and pharmaceuticals were $1.15 billion.


 

BMS

Q1 RESULTS

BMS reported the Q1 revenues of $11.6 billion in 2022. The company's revenues were driven by Eliquis ($3.2 billion), Revlimid ($2.8 billion), Opdivo ($1.9 billion), Pomalyst / Imnovid (0.83 billion), and Orencia (0.79 billion).


H1 REVENUES

BMS reported second-quarter revenues of $11.9 billion, an increase in revenues by 2%.

The total revenues in the first half of 2022 were $23.5 billion, Eliquis revenues increased by 14% ($6.4 billion), Opdivo by 10% ($4.0 billion), and Yervoy by 8% ($1.04 billion). Revlimid revenues decreased by 14% ($5.3 billion).



 

GSK

Q1 RESULTS

GSK reported revenues of $12.3 billion in the first quarter of 2022 (£9.8 billion), a revenue increase of 32% at a constant exchange rate. The biopharmaceutical segment contributed $8.9 billion; consumer health contributed $3.3 billion.

The best-selling drugs were Xevudy ($1.63 billion) and dolutegravir products ($1.38 billion).

 

1 comment

Recent Posts

See All

댓글 1개


ipharmaservices
ipharmaservices
2022년 5월 01일
좋아요
bottom of page